Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nemvaleukin alfa - Alkermes plc

Next Previous
Drug Profile

Nemvaleukin alfa - Alkermes plc

Alternative Names: ALKS-4230; Nemvaleukin; RDB 1450; RDB-1419

Latest Information Update: 01 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alkermes plc
  • Developer Alkermes plc; Merck Sharp & Dohme; Mural Oncology
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Malignant melanoma; Solid tumours; Squamous cell cancer
  • Preclinical Small cell lung cancer

Most Recent Events

  • 26 Mar 2024 Pharmacodynamics and adverse events data from the phase I/II ARTISTRY-3 trial in Solid tumours released by Mural Oncology
  • 02 Aug 2023 Mural Oncology completes the phase-I/II ARTISTRY-1 trial in Solid tumours (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) in Australia, Belgium, Canada, South Korea, Poland, Spain and USA (IV) (NCT02799095)
  • 14 Apr 2023 Pharmacodynamic data from a preclinical study in Malignant melanoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top